Evidence map›Paper›PMID 40079005›Full record

ArticleFrontiers in immunology2025

Multiparameter flow cytometric and transcriptional analyis of CD20 positive T-cells in bone marrow in patients of multiple myeloma and monoclonal gammopathy of undetermined significance.

Barbara Forró, Béla Kajtár, Ágnes Lacza, László Kereskai, Livia Vida, Balázs Kőszegi, Péter Urbán, József Kun, Attila Gyenesei, Szabolcs Kosztolányi and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Barbara ForróDepartment of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
Béla KajtárDepartment of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
Ágnes LaczaDepartment of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
László KereskaiDepartment of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
Livia VidaDepartment of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.
Balázs KőszegiDepartment of Biochemistry and Medical Chemistry, University of Pécs Medical School, Pécs, Hungary.
Péter UrbánGenomics and Bioinformatics Core Facility, Szentágothai Research Centre of the University of Pécs, Pécs, Hungary.
József KunGenomics and Bioinformatics Core Facility, Szentágothai Research Centre of the University of Pécs, Pécs, Hungary.
Attila GyeneseiGenomics and Bioinformatics Core Facility, Szentágothai Research Centre of the University of Pécs, Pécs, Hungary.
Szabolcs Kosztolányi1st Department of Internal Medicine, University of Pécs Medical School, Pécs, Hungary.
Dániel KehlFaculty of Business and Economics, University of Pécs, Pécs, Hungary.
Pál JáksóDepartment of Pathology, University of Pécs Medical School, Clinical Centre, Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: CD20+ T-cells were described firstly in peripheral blood and later in bone marrow in patients with hematological tumors, and certain immune-mediated diseases. During our hematological diagnostic work, this peculiar subgroup of lymphocytes has been consistently observed associated with untreated monoclonal gammopathy of undetermined significance (MGUS) and myeloma (MM). Despite the expanding literature data, the exact function of CD20+ T cells remains unclear. Methods: We investigated the incidence of CD20+ T-cells in MGUS (n=27), and MM using a larger cohort (n=125) and compared it with control bone marrow samples (n=39). We examined their presence before and after treatment in 32 cases with flow cytometry. Comprehensive flow cytometric analysis included the examination of functional (T-cell activation, cytotoxic molecules and T-cell exhaustion) and maturation markers in a large number of cases. In addition RNA sequencing and subsequent bioinformatics analyses were carried out to detect differentially expressed (DE) genes of FACS sorted CD20+ T-cells versus CD20- T-cells. Results and discussion: We found that CD20+ T-cells are phenotypically and transcriptionally different from CD20- T-cells. Elevated incidence of CD20+ T-cells in MGUS and MM and the expression of CD8, NKG2D, and CD28 suggests anti-tumor functionality. Increased PD-1 expression indicates T-cell exhaustion which was mostly detected in the samples of patients with a higher tumor percentage. The majority of CD20+ T-cells are effector or effector memory T-cells. Some of the differentially expressed genes suggest antitumor function via regulating T-cell activation pathways, while other genes involved in tumor escape from immune surveillance by suppressing T-cells or by reprogramming T-cells toward T-cell exhaustion. Our findings suggest that CD20+ T-cells may play a vital role both in immune surveillance and immune escape contributing to progression of multiple myeloma.

Indexed as

Antigens, CD20Bone MarrowMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaT-LymphocytesAgedAged, 80 and overFemaleFlow CytometryHumansImmunophenotypingMaleMiddle AgedAntigens, CD20CD20multiple myelomaT-cell exhaustionT-cellstumor immunology

Identifiers

PMID40079005
PMCPMC11896981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.